RxDoctor Payments DataLook up a doctor →

Tracey Skale, MD

Psychiatry · Cincinnati, OHNPI 1003830647

Payments from drug & device makers

$674,451in general payments, 2019–2025

Across 945 payments — averaging $713.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$275K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$178K
  • AbbVie$151K
  • Sunovion Pharmaceuticals Inc.$21K
  • Alkermes, Inc.$20K
  • E.r. Squibb & Sons, L.L.C.$18K
  • plus $12K from 7 others

What the payments were for

  • Consulting fees$51,0378%
  • Speaking & faculty fees$562,74383%
  • Travel & lodging$48,0287%
  • Food & beverage$12,4892%
  • Education$1540%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$674,451 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$11,119
Medicare patients
36
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate101$334,789
Risperdal ConstaRisperidone Microspheres53$70,834
VraylarCariprazine Hcl39$53,771
Abilify MaintenaAripiprazole12$34,719
FanaptIloperidone22$29,785
Paliperidone ErPaliperidone52$23,891
CaplytaLumateperone Tosylate18$17,528
Chlorpromazine Hcl18$12,103
Quetiapine Fumarate ErQuetiapine Fumarate26$8,714
Clozapine134$7,543
Lurasidone Hcl30$7,474
Olanzapine362$7,470
Haloperidol Decanoate89$7,189
Fluphenazine Hcl48$3,994
Quetiapine Fumarate146$2,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$160$405,623154 claims
AbbVieVraylar$150,675$53,77139 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$275,433$34,71912 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$178,354$17,52818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →